OS Therapies Incorporated (NYSEAMERICAN:OSTX) Short Interest Update

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 1,372,865 shares, a growth of 42.2% from the January 29th total of 965,726 shares. Approximately 4.3% of the company’s stock are short sold. Based on an average daily volume of 662,229 shares, the days-to-cover ratio is currently 2.1 days. Based on an average daily volume of 662,229 shares, the days-to-cover ratio is currently 2.1 days. Approximately 4.3% of the company’s stock are short sold.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. D. Boral Capital reiterated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a research note on Thursday, February 5th. Finally, Lake Street Capital cut their price objective on OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.50.

OS Therapies Stock Up 2.8%

NYSEAMERICAN OSTX traded up $0.04 during trading on Friday, hitting $1.47. The stock had a trading volume of 216,653 shares, compared to its average volume of 461,383. OS Therapies has a twelve month low of $1.12 and a twelve month high of $2.57. The firm has a 50 day moving average price of $1.40 and a 200 day moving average price of $1.77. The company has a market capitalization of $51.76 million, a PE ratio of -1.79 and a beta of -3.79.

Institutional Trading of OS Therapies

A number of large investors have recently made changes to their positions in OSTX. XTX Topco Ltd acquired a new position in OS Therapies during the second quarter worth approximately $63,000. Bridgeway Capital Management LLC acquired a new position in shares of OS Therapies in the second quarter valued at approximately $47,000. Ground Swell Capital LLC acquired a new position in OS Therapies in the 3rd quarter valued at $40,000. CM Management LLC raised its holdings in OS Therapies by 6.7% during the third quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of OS Therapies during the 3rd quarter worth approximately $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.